IART — Integra LifeSciences Holdings Corporation stock price, charts and financials

QT86Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
17.90
+0.02+0.11%
IARTQT86Integra LifeSciences Holdings Corporation·NASDAQ
17.90+0.11%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.09Insider Own17.34%Shs Outstand77.77MPerf Week-9.41%
Market Cap1.39BForward P/E6.87EPS next Y2.61Insider Trans0.00%Shs Float58.68MPerf Month-1.54%
Enterprise Value3.14BPEG-EPS next Q0.57Inst Own-Short Float10.57%Perf Quarter68.08%
Income-8.00MP/S0.84EPS this Y2829.87%Inst Trans-Short Ratio6.06Perf Half Y60.39%
Sales1.65BP/B1.32EPS next Y6.04%ROA-0.20%Short Interest6.21MPerf YTD44.12%
Book/sh13.51P/C5.08EPS next 5Y6.88%ROE-0.69%52W High20.49 -12.64%Perf Year45.41%
Cash/sh3.52P/FCF33.41EPS past 3/5Y-ROIC19.92%52W Low8.70 105.75%Perf 3Y-60.66%
Dividend Est.-EV/EBITDA14.90Sales past 3/5Y1.62% 3.57%Gross Margin53.74%Volatility8.50% 5.60%Perf 5Y-74.86%
Dividend TTM-EV/Sales1.91EPS Y/Y TTM0.22%Oper. Margin39.81%ATR (14)1.10Perf 10Y-54.53%
Dividend Ex-Date-Quick Ratio1.98Sales Y/Y TTM2.30%Profit Margin-0.44%RSI (14)49.00Recom2.73
Dividend Gr. 3/5Y-Current Ratio3.40EPS Q/Q24.44%SMA20-3.18%Beta1.21Target Price20.50
Payout0.00%Debt/Eq1.94Sales Q/Q0.72%SMA501.12%Rel Volume0.69Prev Close17.88
Employees4,427LT Debt/Eq1.81EarningsOct 29SMA20033.98%Avg Volume1.08MPrice17.90
IPO DateAug 16, 1995Option/ShortYes / YesEPS/Sales Surpr.16.54% 0.29%Net Debt/EBITDA8.66Volume748,505Change0.11%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-28-26InitiatedUBSNeutral$19
Jul-16-26ReiteratedTruist SecuritiesHold$12$19
Jul-08-26ReiteratedBMO Capital$19
Jun-18-26ReiteratedArgus ResearchHold$25
May-28-26UpgradeCitigroupSellNeutral
Apr-15-26ReiteratedTruist SecuritiesHold$15$12
Apr-15-26DowngradeArgus ResearchBuyHold
Oct-15-25ReiteratedTruist SecuritiesHold$26$15
Mar-31-25UpgradeArgus ResearchHoldBuy
Oct-07-24UpgradeBTIGSellNeutral$22$20
Latest News
Jul-29-26
Jul-28-26
Jul-23-26
Jul-22-26
Jul-16-26
Jul-15-26
Jul-09-26
Company

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,6481,6351,6111,5421,5581,5421,3721,5181,472
Cost of Goods Sold Incl. D&A763790728657587598521565571
Gross Profit885845882885970945851953901
Selling, General and Administrative Excl. Other688700717657616637595688691
Research and Development959911510410193778078
Other Operating Expense-554-2222121417289121
Operating Income655682811223919715194111
Interest Expense978671515050725465
Unusual Expense
Non-Operating Income (Expense)-560-54624212568142011
Net Income Before Taxes0-564-1881214215946057
Income Taxes7-47-11133346-4010-3
Consolidated Net Income-8-516-7681811691345061
Net Income From Continuing Operations-8-516-7681811691345061
Net Income-8-516-7681811691345061
EPS (Recurring)-0.09-6.73-0.090.872.182.001.580.590.73
EPS (Basic, Before Extraordinaries)-0.09-6.73-0.090.872.182.001.580.590.73
EPS (Diluted)-0.09-6.73-0.090.842.161.981.570.580.72
EBITDA211-326193256385366268224241
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio51.8525.9633.8341.35100.4862.64
Price To Sales Ratio0.850.581.082.202.993.694.023.302.54
Gross Margin53.7051.6854.7557.3962.2661.2862.0362.7861.21
Operating Margin39.754.161.747.2615.3412.7811.016.197.54
Net Margin-0.49-31.56-0.434.4111.6210.969.773.294.14
Shares Outstanding787777788385858683
Market Capitalization1,3969561,7463,3974,6545,6945,5185,0123,743
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$21.49$17.93$14.38$10.82$7.26 Close Price0.00K25.54K51.08K76.61K102.15KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 11 '26Option Exercise0.0037,844040,612Mar 12
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 10 '26Option Exercise0.001,216023,152Mar 12
Poul MojdehPresident & CEOJan 06 '26Option Exercise0.001,39001,390Jan 07
GRAVES JEFFREY ADirectorNov 05 '25Buy11.359,000102,15041,086Nov 06
Singh HarvinderEVP & PRESIDENT, INTERNATIONALOct 12 '25Option Exercise0.0011,965025,217Oct 14
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 11 '25Option Exercise0.002,35604,391Mar 13
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 10 '25Option Exercise0.001,18002,359Mar 11
Schwartz EricEVP, Chief Legal Officer & SecDec 03 '24Sale24.594,070100,10259,511Dec 04
McBreen Michael J.EVP & President, CSSDec 02 '24Sale24.161,70041,06456,182Dec 03
De Witte JanPresident & CEONov 01 '24Option Exercise0.009,814028,164Nov 04
Mosebrook JeffreySVP, Fin & Princ Acct OfficerAug 19 '24Sale21.581,19125,70136,088Aug 20
ESSIG STUARTExec. Chairman of the BoardMay 23 '24Buy28.4952,6411,499,979487,922May 24
HILL BARBARA BDirectorMay 21 '24Buy27.4036,350995,81636,350May 22
De Witte JanPresident & CEOMar 11 '24Option Exercise0.00205018,555Mar 13
De Witte JanPresident & CEOMar 10 '24Option Exercise0.00346018,696Mar 12
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.